<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02564354</url>
  </required_header>
  <id_info>
    <org_study_id>PQ-010-002</org_study_id>
    <nct_id>NCT02564354</nct_id>
  </id_info>
  <brief_title>Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation</brief_title>
  <official_title>Open-Label, Exploratory Study to Evaluate the Effects of QR-010 on Nasal Potential Difference in Subjects With CF With the ΔF508 CFTR Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProQR Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ProQR Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exploratory proof of concept study to determine whether intranasal administration of QR-010
      in subjects with cystic fibrosis, homozygous or compound heterozygous for the ΔF508 mutation,
      can increase the function of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-center, exploratory study to estimate the effect of intranasal
      administration of QR-010 on the nasal mucosa in the restoration of CFTR function, as measured
      by nasal potential difference (NPD), in the nasal epithelium of adult subjects with CF who
      are homozygous or compound heterozygous for the ΔF508 CFTR mutation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-subject change of CFTR-mediated total chloride transport as measured by nasal potential difference (NPD) from baseline through End of Study</measure>
    <time_frame>Baseline, at 2 and 4 weeks, and at 3 weeks post-treatment</time_frame>
    <description>Exploratory Efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with a -6.6 mV or more negative change in CFTR-mediated total chloride transport, and after different treatment durations from baseline through End of Study</measure>
    <time_frame>Baseline, at 2 and 4 weeks, and at 3 weeks post-treatment</time_frame>
    <description>Key Exploratory Efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare CFTR-mediated total chloride transport between dF508 homozygous and compound heterozygous CF subjects from baseline through End of Study</measure>
    <time_frame>Baseline, at 2 and 4 weeks, and at 3 weeks post-treatment</time_frame>
    <description>Exploratory Efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of (serious) adverse events from baseline through End of Study</measure>
    <time_frame>3 weeks post-treatment</time_frame>
    <description>Safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of discontinuations due to AEs from baseline through End of Study</measure>
    <time_frame>3 weeks post-treatment</time_frame>
    <description>Safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormalities of laboratory parameters (chemistry, hematology and urinalysis) from baseline through End of Study</measure>
    <time_frame>3 weeks post-treatment</time_frame>
    <description>Safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormalities of vital signs &amp; oximetry from baseline through End of Study</measure>
    <time_frame>3 weeks post-treatment</time_frame>
    <description>Safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormalities of physical examinations from baseline through End of Study</measure>
    <time_frame>3 weeks post-treatment</time_frame>
    <description>Safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in nasal symptoms (based on the NERS and SNOT-22) from baseline through End of Study</measure>
    <time_frame>3 weeks post-treatment</time_frame>
    <description>Safety and tolerability</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum concentration of QR-010 after intranasal administration</measure>
    <time_frame>30 minutes post dose Baseline, 2 &amp; 4 weeks</time_frame>
    <description>Pharmacokinetics</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum concentration of QR-010 after intranasal administration if persistent AE(s) are present</measure>
    <time_frame>3 weeks post-treatment</time_frame>
    <description>Pharmacokinetics</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in systemic effect of QR-010 as measured by pilocarpine iontopheresis sweat chloride</measure>
    <time_frame>Baseline, at 2 and 4 weeks, and at 3 weeks post-treatment</time_frame>
    <description>Pharmacokinetics</description>
  </other_outcome>
  <other_outcome>
    <measure>Explore correlation between change in nasal potential difference (NPD), sweat chloride (mmol/L), and serum concentration of QR-010</measure>
    <time_frame>Baseline, at 2 and 4 weeks, and at 3 weeks post-treatment</time_frame>
    <description>Exploratory Efficacy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>ΔF508 Homozygous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ΔF508 Compound Heterozygous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QR-010</intervention_name>
    <description>Single-stranded RNA antisense oligonucleotide in isoosmolar solution</description>
    <arm_group_label>ΔF508 Homozygous</arm_group_label>
    <arm_group_label>ΔF508 Compound Heterozygous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of CF as defined by iontophoretic pilocarpine sweat chloride test
             (sweat chloride) of &gt; 60 mmol/L

          -  Nasal potential difference (NPD) measurement at Screening consistent with CF

          -  Confirmation of CFTR gene mutations homozygous or compound heterozygous for the ΔF508
             mutation

          -  Body mass index (BMI) of ≥ 18 kg/m2

          -  Non-smoking for a minimum of 2 years

          -  Stable lung function

          -  FEV1 ≥40% of predicted normal for age, gender, and height at Screening

        Exclusion Criteria:

          -  Breast-feeding or pregnant

          -  Acute allergy or infection affecting nasal conditions not resolved within 14 days
             prior Screening

          -  Use of lumacaftor or ivacaftor

          -  Use of any investigational drug or device

          -  Hemoptysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Clancy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinnati Childrens Hospital Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>November 8, 2016</last_update_submitted>
  <last_update_submitted_qc>November 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>CF</keyword>
  <keyword>ΔF508</keyword>
  <keyword>CFTR</keyword>
  <keyword>QR-010</keyword>
  <keyword>antisense oligonucleotide</keyword>
  <keyword>RNA therapy</keyword>
  <keyword>F508del</keyword>
  <keyword>NPD</keyword>
  <keyword>nasal potential difference</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>February 7, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

